Who are Dayvigo's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quviviq, Suvorexant (Belsomra), Suvorexant High Dose (HD), Dose-matched Placebo to Suvorexant, Suvorexant Low Dose (LD).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lemborexant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Dayvigo — Competitive Intelligence Brief

Dayvigo (LEMBOREXANT) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Orexin Receptor Antagonist [EPC]. Area: Neuroscience.

marketed Orexin Receptor Antagonist [EPC] Orexin receptor type 2 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Dayvigo (LEMBOREXANT) — Eisai. Dayvigo blocks the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dayvigo TARGET	LEMBOREXANT	Eisai	marketed	Orexin Receptor Antagonist [EPC]	Orexin receptor type 2	2019-01-01
Quviviq	DARIDOREXANT	Idorsia	marketed	Orexin Receptor Antagonist [EPC]	Orexin receptor type 1	2022-01-01
Suvorexant (Belsomra)	Suvorexant (Belsomra)	Massachusetts General Hospital	marketed	Orexin receptor antagonist	Orexin receptor 1 (OX1R) and Orexin receptor 2 (OX2R)
Suvorexant High Dose (HD)	Suvorexant High Dose (HD)	Merck Sharp & Dohme LLC	phase 3	Orexin receptor antagonist	OX1R and OX2R (orexin receptors 1 and 2)
Dose-matched Placebo to Suvorexant	Dose-matched Placebo to Suvorexant	Merck Sharp & Dohme LLC	phase 3	Orexin receptor antagonist	OX1R and OX2R (orexin receptors)
Suvorexant Low Dose (LD)	Suvorexant Low Dose (LD)	Merck Sharp & Dohme LLC	phase 3	Orexin receptor antagonist	OX1R and OX2R (orexin receptors 1 and 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Orexin Receptor Antagonist [EPC] class)

Eisai · 1 drug in this class
Idorsia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dayvigo — Competitive Intelligence Brief. https://druglandscape.com/ci/lemborexant. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab